Thanks, Keith. Good morning, everyone. I'll begin with some additional commentary on our operating segments and our major expense categories as well as other key performance indicators. In our occupational health center operating segment, revenue of $463.1 million in Q3 2024 was 3.3% higher than the same quarter of prior year. Keith outlined our 0.7% visit decline year-over-year, driven by the continued and expected lower employer services volume, which are lower-revenue visit, and a 3.9% increase in revenue per visit from $136.11 in Q3 2023 to $141.42 in Q3 2024. Within the center operating segment, workers' compensation revenue of $298.7 million was 4.5% higher than prior year. Q3 2024 work comp visits increased 1.7% from prior year or 0.2% on a per day basis. The Q3 2024 work comp revenue per visit increased 2.7% versus prior year. Workers' compensation revenue represents 64.5% of our total center operating segment revenue in Q3 2024 versus 63.8% in Q3 2023 or a 0.7 percentage point increase. Employer services revenue in the center operating segment of $154.8 million increased 0.9% from prior year. Employer services visits decreased 2.6% from prior year or 4.1% on a per day basis and in line with expectations and continued trends from recent quarters. The Q3 2024 employer services revenue per visit increased 3.6% versus prior year. Onsite revenue of $15.6 million in Q3 increased 3.9% from the same quarter prior year. We had a solid business development quarter in this operating segment, winning more than 10 new onsites that will open in the coming months, including additional onsites with our advanced primary care service offering that we recently launched. Other business revenue of $11 million increased 4.4% against same quarter prior year. Our cost of services expense, excluding depreciation and amortization, a major component of which is personnel costs, includes all direct and indirect support costs related to providing services to our customers. Cost of services was $351.1 million or 71.7% of revenue in Q3 2024 compared to 71.1% of revenue for the same quarter prior year. General and administrative expense includes corporate overheads, such as finance, legal, human resources, marketing, corporate offices and other administrative areas. Our general and administrative expenses were $37.1 million or 7.6% of revenue in Q3 2024 compared to 8.1% of revenue in the same quarter prior year. Our total company labor cost in the quarter was helped by fewer full-time equivalents, or FTEs, quarter-over-quarter despite having 10 more occupational health centers and 11 more onsite health clinics compared to the same quarter prior year. The lower FTEs are primarily in the center operating segment, consistent with prior quarters, where we have fewer FTEs year-over-year largely due to the lower employer services visits. For the third quarter, we had strong cash flow generation, with operating activities providing $65.9 million in cash flow, and our days sales outstanding or DSO at 44 days at September 30, 2024, which was 3 days better than prior year. Our cash flow metrics continued to improve over historical levels. Investing activities used $17 million of cash in the third quarter. This includes $15.1 million in purchases of property and equipment and $1.8 million for the 1 center acquisition in the quarter. Our teams have done a nice job of managing to consistent levels of maintenance and growth capital expenditures each quarter. Financing activities provided $37.2 million of cash for the third quarter. And with the cash retained by the company from the debt and equity transactions in the quarter, we now have a cash balance of $137 million. With our cash flow in the quarter and our higher TTM EBITDA versus June 30, 2024, our total net debt is now $1.35 billion, and our net leverage came down from 3.9x at IPO to 3.7x at September 30, 2024. We still have our undrawn revolver of $400 million, less $14 million of outstanding letters of credit. Given the solid financial performance and following up on previous quarter's comments about a potential dividend, we are pleased to announce that on October 28, 2024, Concentra's Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable on or about November 22, 2024, to stockholders of record as of the close of business on November 13, 2024. From a capital standpoint, we remain focused on growth efforts and deleveraging in addition to this return of capital to stockholders. The dividend does not change our growth outlook and prospects. Now switching gears to our corporate development efforts. In July, we acquired a practice in Bolingbrook, Illinois to further expand our presence in the Greater Chicago area. In September, we opened a new center in Chattanooga, Tennessee, and we are close to opening a new center and nearby Knoxville, Tennessee. Both are new areas for Concentra, and we look forward to providing additional access points nearby in the future. Post quarter end, in early October, we opened a new center in Orlando, Florida as well. We also had a very good quarter in terms of building our acquisition and de novo pipeline. We are excited about some opportunities we are working on and hope to have more information available soon. We intend to pursue continued organic growth within our existing occupational health centers and onsite health clinics at employer worksites and to take advantage of opportunities to continue to grow our footprint and base of customers via strategic acquisitions and the opening of new centers in key areas. Regarding our separation process from Select Medical. As Keith mentioned in his opening remarks, we made solid progress with these efforts, though it is early in the process. We recruited and successfully hired some key senior leaders that will help support the transition, and they have already taken productive steps towards achieving our end goal of operating completely independently from Select Medical before the end of 2026. Our hires include a new Chief Legal Counsel, who has 30-plus years of health care experience; a Vice President of Transition Services and HR, who is an individual with years of prior experience at Concentra and in health care; a Chief Information Security Officer with many years of experience in this area; as well as leaders in accounting and tax to help us replace the services we currently pay Select Medical for. It has been a solid start to the process. Our teams are well synced on what we need to do, the associated costs which have not materially changed from previous estimates. And finally, just some overarching comments for me and the results from the quarter and our outlook for the remainder of the year and beyond. Looking back on what we discussed during the IPO process, we feel good about the progress and execution we have shown since becoming a public company. We discussed how we navigated as a company through economic headwinds, including the negative employer services decline, and we showed that through our execution in the second and third quarters. Our reimbursement rate growth has been strong. It is predictable and is insulated from any election-related uncertainty. Cost of services remains consistent as a percentage of revenue as our teams have managed staffing levels very effectively. Cash flow remains robust and margins consistent with prior periods. Our development pipeline continues to grow. We declared a dividend to show our commitment to returning capital to our stockholders, and we have made good progress with our separation from Select and our latest technology efforts. As we continue our path forward as a public company, we will continue with transparency. To that end, we are providing guidance on where we believe we will end the full year for 2024. We expect revenue to be approximately $1.9 billion, adjusted EBITDA to be in the range of $370 million to $375 million, capital expenditures to be in the range of $65 million to $70 million and our net leverage ratio to be in the range of 3.5x to 3.6x. We will have guidance for 2025 early into the new year. With this information and all the remarks from myself and Keith, we hope investors are becoming more familiar with and excited about Concentra. We believe we remain very well positioned for continued success. With that, this concludes our prepared remarks. Thank you for your time today to go through Concentra's business update and third quarter financial results. At this time, we'd like to turn it back to the operator to open the call for any questions.